Compare MCY & CRNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MCY | CRNX |
|---|---|---|
| Founded | 1961 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9B | 4.1B |
| IPO Year | N/A | 2018 |
| Metric | MCY | CRNX |
|---|---|---|
| Price | $94.03 | $48.27 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 11 |
| Target Price | ★ $100.00 | $71.00 |
| AVG Volume (30 Days) | 199.2K | ★ 992.2K |
| Earning Date | 02-10-2026 | 11-06-2025 |
| Dividend Yield | ★ 1.35% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 7.93 | N/A |
| Revenue | ★ $5,814,768,000.00 | $1,535,000.00 |
| Revenue This Year | $10.03 | $425.41 |
| Revenue Next Year | $4.40 | $943.30 |
| P/E Ratio | $11.85 | ★ N/A |
| Revenue Growth | 5.93 | ★ 47.74 |
| 52 Week Low | $44.19 | $24.10 |
| 52 Week High | $96.50 | $54.18 |
| Indicator | MCY | CRNX |
|---|---|---|
| Relative Strength Index (RSI) | 61.94 | 54.60 |
| Support Level | $91.81 | $43.04 |
| Resistance Level | $96.50 | $49.61 |
| Average True Range (ATR) | 2.10 | 2.04 |
| MACD | -0.08 | -0.16 |
| Stochastic Oscillator | 66.30 | 62.22 |
Mercury General Corp is an insurance holding company. It is engaged in writing personal automobile insurance and provides related property and casualty insurance products. The Company offers the following types of automobile coverage: collision, property damage, bodily injury ("BI"), comprehensive, personal injury protection ("PIP"), underinsured and uninsured motorist, and other hazards. The Company offers the following types of homeowners coverage: dwelling, liability, personal property, and other coverages.
Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its products include Paltusotine and Atumelnant.